Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Actions and Investigations - Shareholders who purchased Telix securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates, leading to a 10.44% drop in the price of Telix's American Depositary Shares on July 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has been recognized for its significant settlements, including over $438 million recovered for investors in 2019 and being ranked among the top firms for securities class action settlements since 2013 [4].

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Synopsys, Inc. securities, alleging that the company made materially false and misleading statements during the class period from December 4, 2024, to September 9, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Synopsys' management failed to disclose significant adverse facts regarding the company's business and operations, particularly related to its focus on artificial intelligence customers, which negatively impacted its Design IP business [5]. - Specific allegations include that the company's decisions were unlikely to yield intended results, which materially affected financial outcomes, and that positive statements made by the defendants were misleading [5]. Group 2: Participation Information - Investors who purchased Synopsys securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being ranked highly for its performance in this area [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the aTyr Pharma common stock is defined as January 16, 2025, to September 12, 2025, inclusive [2]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 8, 2025 [4]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time [5]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [5]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading nature of the statements made by the company [6].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased or sold Cepton common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 8, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Cepton's business and operations [5]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - The Board of Directors allegedly failed to explore this offer meaningfully and did not disclose its terms, depriving shareholders of the opportunity to consider the acquisition [5].

Core Viewpoint - Rosen Law Firm is reminding sellers of ordinary shares of Sina Corporation about the upcoming lead plaintiff deadline in a securities class action related to the Merger that occurred between October 13, 2020, and March 22, 2021 [1][2]. Group 1: Class Action Details - Sellers of Sina ordinary shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit alleges that defendants created a fraudulent scheme to depress the value of Sina ordinary shares to avoid paying a fair price during the Merger [5]. Group 2: Allegations Against Defendants - The defendants are accused of misrepresenting and omitting material information in Sina's proxy materials, which were necessary for shareholders to make informed decisions regarding the Merger [5]. - Specific allegations include the concealment of the true value of Sina's investment in TuSimple and that the offered price of $43.30 per ordinary share significantly undervalued Sina's shares [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who purchased or sold Cepton common stock between July 29, 2024, and January 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Cepton's business and operations [5] - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5] - The Board of Directors allegedly failed to explore the third-party offer meaningfully and did not disclose its terms, depriving shareholders of the opportunity to consider the Koito Acquisition [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to ensure proper manufacturing processes increased the risk of confounding study results, leading to overstated business and financial prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of CarMax, Inc. securities purchasers during the specified Class Period, alleging that the company made materially false and misleading statements regarding its growth prospects [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between June 20, 2025, and September 24, 2025 [1]. - The lawsuit claims that CarMax's growth was overstated due to temporary factors, specifically customer purchases driven by speculation about tariffs [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by January 2, 2026, to represent the class in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking in the top 4 since 2013 [4].